news

CUPERTINO, Calif., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) and Voyager Pharmaceutical Corporation announced today that the two companies have signed a development and commercialization agreement to develop Voyager’s patented product, using leuprolide acetate for the treatment of Alzheimer’s disease. Voyager owns the patent rights to the use of a broad […]

CUPERTINO, Calif., Jul 9, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing of patients in the first clinical trial of its pivotal Phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System. The CHRONOGESIC product is a pain relief system that continuously delivers sufentanil systemically for three

CUPERTINO, Calif., Jul 8, 2002 /PRNewswire-FirstCall via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 29, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive

CUPERTINO, Calif., Jun 11, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Goldman Sachs Twenty – Third Annual Global Healthcare Conference. The conference is being held at The Ritz – Carlton, Laguna Niguel in California. Dr. Felix Theeuwes, Chairman & Chief Scientific Officer will be presenting

CUPERTINO, Calif., Jun 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the UBS Warburg Global Specialty Pharmaceuticals Conference. The conference is taking place June 5-6, 2002 at the Grand Hyatt New York. Thomas A. Schreck, Chief Financial Officer will be presenting at the conference on Thursday,

CUPERTINO, Calif., Apr 29, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place May 1-2, 2002 at The Millennium Hotel in New York. Dr. Felix Theeuwes, Chairman & Chief Scientific Officer will be

CUPERTINO, Calif., Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2002. DURECT’s net loss for the three months ended March 31, 2002 was $9.7 million or 20 cents per share, compared to $4.9 million or 11 cents per share for the

CUPERTINO, Calif., Apr 8, 2002 (BUSINESS WIRE) — In conjunction with DURECT Corporation’s (Nasdaq:DRRX) first quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, April 24, 2002 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom

CUPERTINO, Calif., Apr 2, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed an Investigational New Drug application to investigate the delivery of cromolyn sodium for the treatment of asthma. This IND was filed as part of an ongoing program to develop a product for the treatment of asthma

CUPERTINO, Calif., Mar 27, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today a collaboration with Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services Center, Inc. to explore the feasibility of producing long acting soft gelatin based oral products, using the SABER(TM) technology as core formulations. The technology has the potential of greatly